Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test

Lorenzi, Adriana Tarlá; Fregnani, José Humberto Tavares Guerreiro; Possati-Resende, Júlio César; Scapulatempo‐Neto, Cristovam; Villa, Luisa L.; Longatto‐Filho, Adhemar

doi:10.1016/j.ygyno.2013.07.092

Cited by 35 publications

(36 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specialized training and education are not required to run the test. It has been evaluated in multiple countries and found that careHPV is a sensitive and reasonably specific screening test for cervical precancer and cancer (7)(8)(9)(10)(11)(12). In 2012, the China Food and Drug Administration approved this test for cervical cancer screening (13).…”

mentioning

confidence: 99%

Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China

et al. 2014

View full text Add to dashboard Cite

d careHPV, a lower-cost DNA test for human papillomavirus (HPV), is being considered for cervical cancer screening in low-and middle-income countries. However, not a single large-scaled study exists to investigate the optimal positive cutoff point of careHPV test. We pooled data for 9,785 women participating in two individual studies conducted from 2007 to 2011 in rural China. Woman underwent multiple screening tests, including careHPV on clinician-collected specimens (careHPV-C) and selfcollected specimens (careHPV-S), and Hybrid Capture 2 on clinician-collected specimens (HC2-C) as a reference standard. The primary endpoint was cervical intraepithelial neoplasia grade 3 or more severe (CIN3؉) (n ‫؍‬ 127), and secondary endpoint was CIN2؉ (n ‫؍‬ 213). The area under the curves (AUCs) for HC2-C and careHPV-C were similar (0.954 versus 0.948, P ‫؍‬ 0.166), and better than careHPV-S (0.878; P < 0.001 versus both). The optimal positive cutoff points for HC2-C, careHPV-C, and careHPV-S were 1.40, 1.74, and 0.85, respectively. At the same cutoff point, careHPV-C was not significantly less sensitive and more specific for CIN3؉ than HC2-C, and careHPV-S was significantly less sensitive for CIN3؉ than careHPV-C and HC2-C. Raising the cutoff point of careHPV-C from 1.0 to 2.0 could result in nonsignificantly lower sensitivity but significantly higher specificity. Similar results were observed using CIN2؉ endpoint. careHPV using either clinician-or self-collected specimens performed well in detecting cervical precancer and cancer. We found that the optimal cutoff points of careHPV were 2.0 on clinician-collected specimens and 1.0 on self-collected specimens.

show abstract

mentioning

confidence: 99%

Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The results of the current study are consistent with those of other studies regarding HPV detection in Brazilian women. de Aguiar Original Article et al, 25 Lorenzi et al, 19 Rosa et al, 26 and Nonnenmacher et al 27 reported HPV prevalence rates of 10.5%, 12.3%, 12.3%, and 15%, respectively. The majority of these women lived in rural or remote areas of Brazil and experienced difficulties in accessing medical care or the heath assistance infrastructure.…”

Section: Discussionmentioning

confidence: 99%

“…This method can detect 14 types of hr-HPV (types 16,18,31,33,35,39,45, 51, 52, 56, 58, 59, 66, and 68), and >90 specimens can be processed within 2.5 hours. 12,13,19 …”

Section: Carehpv Testmentioning

confidence: 99%

“…The careHPV test detects 14 types of hr-HPV (types 16,18,31,33,35,39,45,51,52,56,58,59, 66, and 68) in cervical specimens 13,14,19,20 and exhibits high sensitivity and specificity in the detection of precancerous and cancerous cervical lesions. 19,[21][22][23][24] Populations in many Brazilian regions have difficulty accessing public health assistance because many individuals reside in areas that are a distance from medical care facilities, roads (when they exist) are extremely bad, and public transportation is lacking.…”

Section: Introductionmentioning

confidence: 99%

“…19,[21][22][23][24] Populations in many Brazilian regions have difficulty accessing public health assistance because many individuals reside in areas that are a distance from medical care facilities, roads (when they exist) are extremely bad, and public transportation is lacking. These conditions represent some of the principle motivations for the Barretos Cancer Hospital (BCH) to introduce the use of mobile units (MUs) in 1994 to attend to populations living in remote rural areas, including the midwest, southwest, and northern (Amazon) regions of Brazil; women in these regions comprise a significant percentage of the Brazilian population with HPV-induced lesions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?

Lorenzi

Fregnani

Possati-Resende

et al. 2016

Cancer Cytopathology

Self Cite

View full text Add to dashboard Cite

Evaluating human papillomavirus (HPV) self‐sampling among Latinas in the United States: A systematic review

Cora‐Cruz,

Martinez,

Perez

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundLatinas experience the greatest cervical cancer incidence compared with other ethnic/racial groups in the United States (US) due in part to significant disparities in screening uptake. Social and structural conditions that impede access to and participation in screening include language barriers, concerns about documentation status, logistical issues (e.g., transportation, limited clinic hours), and cultural beliefs regarding modesty and promiscuity. To overcome these challenges, self‐sampling for human papillomavirus (HPV) DNA testing has emerged as a potentially promising method for promoting cervical cancer screening among this population. Thus, this systematic review aimed to assess the acceptability of HPV self‐sampling among US Latinas.MethodsUsing EBSCOhost and PubMed databases, we searched for studies published in the past two decades (2003–2023) that described participation in HPV self‐sampling among Latinas. Eleven articles met inclusion criteria.ResultsThe majority of studies were conducted in Florida, California, and Puerto Rico, were single‐arm designs, and involved the use of community health workers and Spanish‐language materials (e.g., brochures). Across studies, the majority of participants reported that self‐sampling was acceptable with respect to ease of use, comfort (lack of pain), privacy, and convenience; however, some women were concerned about the accuracy of self‐sampling or whether they had performed sample collection correctly.ConclusionGiven the high acceptability, self‐collection of cervicovaginal samples for HPV testing may offer a feasible option for enhancing participation in cervical cancer screening in this population that encounters significant barriers to screening.

show abstract

Self-collection for high-risk HPV detection in Brazilian women using the careHPV™ test

Abstract: Self-sampled and health professional-sampled vaginal/cervical specimens did not differ in their rates of detection of hr-HPV. Therefore, HPV DNA testing in self-sampled vaginal cells is an alternative to primary screening in low-resource settings.

Cited by 35 publications

References 13 publications

Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China

Optimal Positive Cutoff Points for careHPV Testing of Clinician- and Self-Collected Specimens in Primary Cervical Cancer Screening: an Analysis from Rural China

Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?

Evaluating human papillomavirus (HPV) self‐sampling among Latinas in the United States: A systematic review

Contact Info

Product

Resources

About